Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 7/20 | 0.45 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | JUN | P05412 | 2/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.41 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16514893 | 0.96 | SRC (0.47) | ITKJAK2PTK2JAK3SRC | |
| SCHEMBL16515135 | 0.92 | SRC (0.43) | JAK2PTK2JAK3TP53MAPT | |
| SCHEMBL16513558 | 0.91 | AIMP2 (0.42) | ITKSRC | |
| SCHEMBL16513622 | 0.90 | SRC (0.49) | ITKJAK2PTK2JAK3SRC | |
| SCHEMBL16515145 | 0.89 | JAK2 (0.46) | ITKJAK2JAK3TP53MAPT | |
| SCHEMBL29848007 | 0.89 | JAK2 (0.44) | ITKJAK2PTK2JAK3TP53 | |
| SCHEMBL29848276 | 0.89 | JAK2 (0.46) | ITKJAK2JAK3TP53MAPT | |
| SCHEMBL16515085 | 0.89 | JAK2 (0.44) | ITKJAK2PTK2JAK3TP53 | |
| SCHEMBL16514223 | 0.88 | ERBB3 (0.42) | ITKJAK2PTK2TP53MAPT | |
| SCHEMBL29847634 | 0.88 | ERBB3 (0.42) | ITKJAK2PTK2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105682661-B | Certain chemical entities, compositions, and methods | 润新生物公司 | 2020-03-27 | — | — | CN | claimed |
| US-9849139-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-12-26 | — | — | US | claimed |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2017-07-13 | — | — | US | claimed |
| US-9550770-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-01-24 | — | — | US | claimed |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC (US) | 2025-09-02 | — | — | US | disclosed |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA INC | 2024-06-20 | — | — | US | disclosed |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2022-11-10 | — | — | US | disclosed |
| CN-109851617-B | Chemical entities, compositions, and methods | 润新生物公司 | 2022-08-16 | — | — | CN | disclosed |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2022-04-19 | — | — | US | disclosed |
| US-20200306259-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2020-10-01 | — | — | US | disclosed |
| US-10653701-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| CN-105682661-B | Certain chemical entities, compositions, and methods | 润新生物公司 | 2020-03-27 | — | — | CN | disclosed |
| US-20190307767-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3508204-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2019-07-10 | — | — | EP | disclosed |
| EP-3035936-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-9849139-B2 | Substituted quinazolines for inhibiting kinase activity | NEUPHARMA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | NEUPHARMA, INC. | 2017-07-13 | — | — | US | disclosed |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307767-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | ITK 417/4885JAK2 356/4885PTK2 265/4885 |
| US-20170196881-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | ITK 417/4885JAK2 356/4885PTK2 265/4885 |
| US-20240197752-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | ITK 417/4885JAK2 356/4885PTK2 265/4885 |
| US-11865120-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | ITK 417/4885JAK2 356/4885PTK2 265/4885 |
| US-12403145-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | ITK 417/4885JAK2 356/4885PTK2 265/4885 |
| US-10653701-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | ITK 417/4885JAK2 356/4885PTK2 265/4885 |
| US-11304957-B2 | Substituted quinazolines for inhibiting kinase activity | DCK, ABL1, MAP4K2 | ITK 417/4885JAK2 356/4885PTK2 265/4885 |
| US-20200306259-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | ITK 417/4885JAK2 356/4885PTK2 265/4885 |
| US-20220354864-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | DCK, ABL1, MAP4K2 | ITK 417/4885JAK2 356/4885PTK2 265/4885 |
| US-20170050936-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CDK2, MAP3K6, MAP3K2 | ITK 860/4885JAK2 248/4885PTK2 164/4885 |
| US-20260102406-A1 | SUBSTITUTED QUINAZOLINES FOR INHIBITING KINASE ACTIVITY | BRAF, TTK, MAP4K2 | ITK 24/4885JAK2 155/4885PTK2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.